Brief: Edgewise Therapeutics Doses First Patient In Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics

06/05/2024 13:10

May 6 (Reuters) - Edgewise Therapeutics Inc  EWTX.O :
    * EDGEWISE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 2
CIRRUS-HCM
TRIAL OF EDG-7500 IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
(HCM)
    * EDGEWISE THERAPEUTICS - EXPECTS TO REPORT DATA FROM SINGLE
DOSE
ARM OF THIS TRIAL AND A PHASE 1 TRIAL OF EDG-7500 IN HEALTHY
VOLUNTEERS IN Q3 OF 2024
    * EDGEWISE THERAPEUTICS INC - EXPECTS TO BEGIN AN OPEN-LABEL
EXTENSION TRIAL OF EDG-7500 IN Q4 OF 2024
    * EDGEWISE THERAPEUTICS INC - EXPECTS TO INITIATE A 28-DAY
TRIAL
IN PATIENTS WITH OBSTRUCTIVE AND NON-OBSTRUCTIVE HCM IN SECOND
HALF OF 2024

Source text for Eikon:  ID:nBw49Xt3ma 
Further company coverage:  EWTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))